News

ELITechGroup

Filter

Open filter menu
Reset
Reset

ELITechGroup achieves a new CE-IVDR Certification

ELITechGroup continues to expand its portfolio of IVDR-certified PCR assays to support European diagnostic laboratories The newly obtained IVDR certificate will expedite the transition to IVDR for quantitative Class C infectious diseases assays The company is fully committed to delivering its entire portfolio of nearly 60 molecular assays as IVDR…

ELITechGroup Launches Second IVDR Certified Gastrointestinal Infection Assay: GI Parasitic PLUS ELITe MGB® Kit 

ELITechGroup launches their second kit of the Gastrointestinal infection assay panel targeting parasitic pathogens.  The ELITe MGB Gastrointestinal assays are IVDR-certified in combination with InGenius and BeGenius, fully automated samples-to-results instruments.  The company will shortly launch two more gastrointestinal assay infection panels targeting viral pathogens and Norovirus.   ELITechGroup announces the…

ELITechGroup launches CE-IVDR certified GI Bacterial PLUS ELITe MGB® Kit and expands in vitro diagnostic portfolio

ELITechGroup launches their first kit of the Gastrointestinal assay panel targeting bacterial pathogens. ELITechGroup is planning to launch three additional kits covering the full range of gastrointestinal infections within the next quarter. In a significant move towards advancing global diagnostic capabilities, ELITechGroup proudly announces the introduction of the GI Bacterial…

Honoring ELITechGroup’s Legacy: The MGB Stabilizer Revolution

In the world of molecular diagnostics, we often encounter groundbreaking innovations that deserve a tribute. Today, we pay homage to a pivotal moment in history—the invention of the MGB stabilizer, i.e., Minor Groove Binder stabilizer, by ELITechGroup MDx LLC (formerly known as Epoch Biosciences) in 1995. This unsung hero has…

ELITechGroup obtains new IVDR certificate for PCR assays

After the release of the first IVDR certificate at the beginning of the year ELITech Group continues to expand its portfolio of IVDR-certified PCR assays to support European diagnostic laboratories. The company is fully committed to delivering its entire portfolio of nearly 60 molecular assays as IVDR compliant by 2026…

ELIVERSE: the video teaser

https://www.elitechgroup.com/news/wp-content/uploads/sites/33/2023/04/Eliver-Teaser-1.1-1-1.mp4   ElitechGroup Mdx is pleased to announce that ELIVERSE will be launched in Europe in 2024. With its introduction, ELITechGroup will have launched three molecular sample-to-result platforms in 8 years. Read the press release here.

ELITechGroup Molecular inaugurates its new headquarter in Turin

Turin, 22nd December 2022 – ELITechGroup has inaugurated its new headquarters in Turin, becoming one of the largest molecular biology hubs in Europe. The inauguration was held on Friday 16th December in the presence of institutional figures, collaborators, and employees. At the ribbon cutting, Michela Favaro – Deputy Mayor of…

ELITe InGenius™ nominated for Scientists’ Choice Awards®!

  ELITe InGenius™ nominated for Scientists’ Choice Awards! Each year the Scientists’ Choice Awards® celebrates the laboratory products and manufacturers that make a difference to the industry. SelectScience began the Scientists’ Choice Awards® in 2007 to enable scientists to voice their opinions on the best laboratory products. Scientists are then…

ELITechGroup receives CE mark

ITALY, Torino, December 9th, 2021. ELITechGroup announced today that its SARS-CoV-2 Extended ELITe MGB® Kit reliably differentiates the SARS-CoV-2 Omicron (B.1.1.529) variant from other variants of concern. The in-silico analysis was confirmed by testing patient samples positive for different SARS-CoV-2 variants including Omicron. ELITechGroup is pleased to offer the SARS-CoV-2…

Our new Molecular MDR/MTB multiplex assay

Een high performance based on our MGB® technology: – MTB complex: M.tuberculosis, M.africanum, M.bovis, M.canetti, M.microti, M.caprae. – MGB resistence: Rifampicine en Izoniazide. – Ultra sensitive: 6CFU/ml! – Ready to use monoreagent. In combination with our RT-PCR Sample-to-Result ELITe InGenius the most flexible solution for the diagnosis of Tuberculosis. “

ELITechGroup soutient AIDES & La ligue contre le cancer

Puteaux, France, le 15 Avril 2022, (14h CEST) ELITechGroup, fabricant et distributeur d’équipements et de réactifs de diagnostic in vitro, a annoncé apporter son soutien en offrant une aide financière auprès de deux associations françaises : AIDES et La Ligue contre le canc ELITechGroup, acteur incontournable de la biologie moléculaire,…

ELITechGroup supports AIDES & La Ligue contre le cancer

Puteaux, France, April 28th, 2022 – ELITechGroup, manufacturer and distributor of in vitro diagnostic instruments and reagents, has announced its charitable contributions to two French associations: AIDES and La Ligue contre le cancer. ELITechGroup, a key player in molecular biology diagnostics and clinical chemistry, brings together the expertise of innovative…

ELITechGroup’s donation to support Ukraine

Turin, 5th April, 2022 – ELITechGroup donated € 30,000 to provide emergency aid to Ukraine in response to the humanitarian crisis. Given the dramatic situation in Ukraine, ELITechGroup took immediate action to collaborate with SERMIG, a non-profit organisation based in Turin, Italy, with more than 50 years of experience in…

ELITechGroup celebrates the installation of the 1000th ELITe InGenius® system

Turin, 23rd December, 2021 – It is with great satisfaction that ELITechGroup announces the installation of the 1000th ELITe InGenius® system. This milestone – achieved only 5 years after the launch of the product – clearly demonstrates the worldwide success of the company’s fully automated sample-to-result Real Time PCR platform.…

A PCR kit that differentiates the SARS-CoV-2 Omicron Variant

Bothell, WA December 10, 2021 ELITechGroup MDx LLC (“ELITechGroup MDx”) announced today that its Research Use Only (RUO) SARS-CoV-2 Extended test kit reliably differentiates the SARS-CoV-2 Omicron (B.1.1.529) variant from other variants of concern. The in-silico analysis was confirmed by testing patient samples positive for different SARS-CoV-2 variants including Omicron.…